A phase 2/3, multicenter, open-label, multicohort study evaluating pharmacokinetics (PK), safety, and efficacy of cobicistat-boosted Atazanavir (ATV/co) or cobicistat-boosted Darunavir (DRV/co) and Emtricitabine/Tenofovir Alafenamide (F/TAF) in HIV-1 infected, virologically suppressed pediatric participants

This study assessed the safety and efficacy of Cobicistat-boosted Atazanavir (ATV/co) or Cobicistat-boosted Darunavir (DRV/co) and Emtricitabine/Tenofovir Alafenamide (F/TAF) among children. However, it later became a long-term cohort. All of the participants are still followed. Now, all of the participants are > 18 years old.